ClinicalTrials.gg
CompletedNCT05741372Updated Jan 13, 2026Results posted

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

An interventional study of Rosuvastatin and Digoxin in Liver Cirrhosis, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Boehringer Ingelheim · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Liver Cirrhosis with a site in Germany — 24 open to participants now, 27 under way, 2 of them phase 3. Liver Cirrhosis · Germany.

Enrollment
35th of 43
28 · median 110
Started
2023
with 9 others
No phase
12 of 82
6 open now
Registered
61st of 82
by date
Lead sponsor
5 of 82
Boehringer Ingelheim

Among the 82 studies in Liver Cirrhosis with a site in Germany, this one is the 35th largest by enrollment of the 43 interventional ones that give a count, is one of 10 that started in 2023, is one of 12 with no phase, and was the 61st registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

24 of the 82 studies in Liver Cirrhosis with a site in Germany are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Liver Cirrhosis with a site in Germany, or all of them as a file.
02

Study summary

This study is open to healthy adults and adults with liver cirrhosis. The purpose of this study is to compare how different medicines are handled by the body in people with and without liver cirrhosis. The study measures if the approved medicines rosuvastatin, digoxin, metformin, and furosemide are processed differently in people with liver cirrhosis than in people without liver cirrhosis.

This study will help to understand how new medicines being developed are handled by the body in people with liver cirrhosis. There are 3 groups in this study: people without liver cirrhosis, people with mild liver cirrhosis, and people with moderate liver cirrhosis. All participants get 1 dose each of rosuvastatin, digoxin, metformin, and furosemide by mouth. The participants with liver cirrhosis continue their regular treatment for the condition during the study.

Participants are in the study for about 1 month. During this time, they visit the study site 4 times. For 1 of the visits, they stay overnight for 2 nights at the study site. To assess the main study endpoint, the doctors take frequent blood samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Liver Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria

Healthy subjects and F4 liver cirrhosis patients:

  • Signed and dated written in accordance with the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  • Either male subject, or female subject who meets any of the following criteria for a highly effective from at least 30 days before the first administration of trial medication until 30 days after trial completion:

    • Use of combined (estrogen and progestogen containing) hormonal contraception that prevents ovulation (oral, intravaginal, or transdermal), plus condom
    • Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants), plus condom
    • Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
    • Sexually abstinent
    • A vasectomized sexual partner who received medical assessment of the surgical success (documented absence of sperm) and provided that the partner is the sole sexual partner of the trial participant
    • Surgically sterilized (including hysterectomy)
    • , defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of follicle-stimulating hormone (FSH) above 40 units per liter (U/L) and estradiol below 30 nanograms per liter (ng/L) is confirmatory)
    • Not taking any components in the cocktail within 4 weeks of enrolment

Healthy subjects only:

  • Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 75 years (inclusive)
  • (BMI) of 18.5 to 35 kilograms per meter squared (kg/m2) (inclusive). A BMI of ≥ 30 is no exclusion criterion when the subject can be considered healthy apart from the elevated BMI
  • further inclusion criteria apply

F4 liver cirrhosis patients only:

  • Male and female subjects, 18 to 75 years
  • BMI of 18.5 to 40.0 kg/m2 (inclusive)
  • Stable treatment for at least 4 weeks prior to taking the cocktail
  • further inclusion criteria apply

Healthy subjects and F4 liver cirrhosis patients:

  • Subjects already taking digoxin, furosemide, metformin or rosuvastatin within 4 weeks of enrolment into the study. Furthermore, patients taking ezetimibe, fibrates, or the maximal dose (per Summary of Product Characteristics (SmPC)) of any statin are excluded from this study.
  • Subjects with any other condition that would preclude administration of digoxin, furosemide, metformin or rosuvastatin (i.e., as per SmPC), such as to active ingredient or any of the or to sulphonamides, hypovolemia or dehydration, and partial obstructions of urinary outflow (e.g., prostatic hypertrophy)
  • Repeated measurement of systolic blood pressure outside the range of 90 to 150 millimeter of mercury (mmHg), diastolic blood pressure outside the range of 50 to 95 mmHg, or pulse rate outside the range of 60 to 90 beats per minute (bpm)
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Relevant (other than virus (HBV) or virus (HCV)) chronic or acute infections (including an ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection)
  • Patients receiving antiviral therapy at the time of inclusion into the trial
  • further exclusion criteria apply
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Group 1: Healthy participants

    Healthy participants received a single dose of the following cocktail on Day 1 after a standardized light breakfast and 280 ml of water: 0.25 milligrams (mg) digoxin as tablet, 1 mg furosemide as 0.1 milliliters (ml) oral solution, 10 mg metformin hydrochloride as 0.05 ml oral solution and 10 mg rosuvastatin as film-coated tablet.

    Drug: Rosuvastatin · Drug: Digoxin · Drug: Metformin hydrochlorid · Drug: Furosemide

  • Experimental
    Group 2: F4 Child-Turcotte-Pugh class A (Child-Pugh A) subjects (compensated)

    Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A received a single dose of the following cocktail on Day 1 after a standardized light breakfast and with 280 ml of water: 0.25 milligrams (mg) digoxin as tablet, 1 mg furosemide as 0.1 milliliters (ml) oral solution, 10 mg metformin hydrochloride as 0.05 ml oral solution and 10 mg rosuvastatin as film-coated tablet. Compensated=without any disease symptoms

    Drug: Rosuvastatin · Drug: Digoxin · Drug: Metformin hydrochlorid · Drug: Furosemide

  • Experimental
    Group 3: F4 Child-Turcotte-Pugh class B (Child-Pugh B) subjects (decompensated)

    Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that met the criteria for Child-Pugh B received a single dose of the following cocktail on Day 1 after a standardized light breakfast and with 280 ml of water: 0.25 milligrams (mg) digoxin as tablet, 1 mg furosemide as 0.1 milliliters (ml) oral solution, 10 mg metformin hydrochloride as 0.05 ml oral solution and 10 mg rosuvastatin as film-coated tablet. Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome

    Drug: Rosuvastatin · Drug: Digoxin · Drug: Metformin hydrochlorid · Drug: Furosemide

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

  2. Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

  3. Area Under the Concentration Time Curve of Digoxin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

  4. Maximum Measured Concentration of Digoxin in Plasma (Cmax)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

  5. Area Under the Concentration Time Curve of Metformin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

  6. Maximum Measured Concentration of Metformin in Plasma (Cmax)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

  7. Area Under the Concentration Time Curve of Furosemide in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

  8. Maximum Measured Concentration of Furosemide in Plasma (Cmax)

    Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

    Time frame: Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.

07

Results

Posted Jan 13, 2026

Participant flow

The purpose of this single dose, open label study was to investigate whether the maximum concentration (Cmax) and the area under the concentration-time curve of the analyte in plasma from time point 0 to time point 24 hours (AUC0-24) values for the different components in the transporter cocktail - digoxin, furosemide, metformin and rosuvastatin are similar or different in F4 graded liver fibrosis (cirrhosis) patients on standard therapy compared to healthy participants.

Participant flow — Overall Study
MilestoneGroup 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Started11116
Completed11116
Not completed000

Outcome measures

PrimaryArea Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · hours*nanomole/liters (h*nmol/l)
Area Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
hours*nanomole/liters (h*nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Area Under the Concentration Time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)94.5 ± NA120.2 ± NA704.6 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 127.2 · 90% CI 85.4 to 189.6Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 23.6%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 745.7 · 90% CI 464.9 to 1196Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 28.1%.
PrimaryMaximum Measured Concentration of Rosuvastatin in Plasma (Cmax)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · nanomole/liters (nmol/l)
Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)
nanomole/liters (nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax)9.8 ± NA17.9 ± NA167.1 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 183.6 · 90% CI 117.3 to 287.5Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 26.6%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 1712.2 · 90% CI 1006.7 to 2912.2Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 31.7%.
PrimaryArea Under the Concentration Time Curve of Digoxin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · hours*nanomole/liters (h*nmol/l)
Area Under the Concentration Time Curve of Digoxin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
hours*nanomole/liters (h*nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Area Under the Concentration Time Curve of Digoxin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)8.1 ± NA7.8 ± NA7.6 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 96.6 · 90% CI 81.0 to 115.3Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 10.3%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 93.6 · 90% CI 75.9 to 115.3Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 12.2%.
PrimaryMaximum Measured Concentration of Digoxin in Plasma (Cmax)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · nanomole/liters (nmol/l)
Maximum Measured Concentration of Digoxin in Plasma (Cmax)
nanomole/liters (nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Maximum Measured Concentration of Digoxin in Plasma (Cmax)1.7 ± NA1.3 ± NA1.4 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 78.9 · 90% CI 63.8 to 97.5Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 12.5%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 83.6 · 90% CI 65.0 to 107.5Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 14.8%.
PrimaryArea Under the Concentration Time Curve of Metformin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · hours*nanomole/liters (h*nmol/l)
Area Under the Concentration Time Curve of Metformin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
hours*nanomole/liters (h*nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Area Under the Concentration Time Curve of Metformin in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)2035.7 ± NA1982.8 ± NA1917.9 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 97.4 · 90% CI 83.2 to 114Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 9.2%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 94.2 · 90% CI 78.2 to 113.5Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 10.9%.
PrimaryMaximum Measured Concentration of Metformin in Plasma (Cmax)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · nanomole/liters (nmol/l)
Maximum Measured Concentration of Metformin in Plasma (Cmax)
nanomole/liters (nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Maximum Measured Concentration of Metformin in Plasma (Cmax)348.0 ± NA303.6 ± NA291.0 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 87.3 · 90% CI 74.0 to 102.9Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 9.7%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 83.6 · 90% CI 68.8 to 101.7Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 11.5%.
PrimaryArea Under the Concentration Time Curve of Furosemide in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · hours*nanomole/liters (h*nmol/l)
Area Under the Concentration Time Curve of Furosemide in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)
hours*nanomole/liters (h*nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Area Under the Concentration Time Curve of Furosemide in Plasma Over the Time Interval From 0 to 24 Hours (AUC0-24)238.0 ± NA210.1 ± NA275.0 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 88.3 · 90% CI 71.6 to 108.8Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 12.2%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 115.5 · 90% CI 90.2 to 148.0Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 14.5%.
PrimaryMaximum Measured Concentration of Furosemide in Plasma (Cmax)

Adjusted geometric means and adjusted geometric standard errors were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetics endpoint was log transformed (natural logarithm) prior to fitting the ANOVA model. This model included effects accounting for the following sources of variation: 'group', age, and BMI. All effects were considered as fixed.

Time frame:
Within 2 hours (hrs) before and at 30 minutes (min), 1 hrs, 1.5 hrs, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, and 24 hrs after drug administration.
Reported as:
Geometric least squares mean · nanomole/liters (nmol/l)
Maximum Measured Concentration of Furosemide in Plasma (Cmax)
nanomole/liters (nmol/l)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
Maximum Measured Concentration of Furosemide in Plasma (Cmax)81.1 ± NA62.3 ± NA78.0 ± NA
Statistical analysis
  • Group 1: Healthy Participants vs Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated) · Adjusted geometric mean ratio: 76.8 · 90% CI 61.1 to 96.6Ratio \[%\]=(adjusted geometric mean Group 2/adjusted geometric mean Group 1)\*100. Total gCV = 13.4%.
  • Group 1: Healthy Participants vs Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated) · Adjusted geometric mean ratio: 96.2 · 90% CI 73.4 to 126.1Ratio \[%\]=(adjusted geometric mean Group 3/adjusted geometric mean Group 1)\*100. Total gCV = 15.9%.

Adverse events

Collected over For AEs on-treatment period: From start of drug administration on Day 1 plus longest residual effect period for drugs in the cocktail, up to 10 days. For all-cause mortality: From start of drug administration until end of follow-up, up to 18 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Healthy Participants0/11 (0%)0/11 (0%)3/11 (27.3%)
Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)0/11 (0%)0/11 (0%)3/11 (27.3%)
Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)0/6 (0%)0/6 (0%)0/6 (0%)
Most frequent other events
Most frequent other events
EventGroup 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)
HeadacheNervous system disorders2/112/110/6
Taste disorderNervous system disorders0/111/110/6
DiarrhoeaGastrointestinal disorders1/110/110/6
NasopharyngitisInfections and infestations1/110/110/6

Baseline characteristics

Treated set (TS): The treated set included all subjects who signed informed consent and were treated with at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)Total
Mean58.5 ± 8.960.2 ± 11.961.2 ± 13.559.7 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)Total
Female66214
Male55414
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)Total
Hispanic or Latino0000
Not Hispanic or Latino1111628
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Healthy ParticipantsGroup 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)Group 3: F4 Child-Turcotte-Pugh Class B (Child-Pugh B) Subjects (Decompensated)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1111628
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g., studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https:// www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2024, 15 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 215 interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 23, 2023
StartActual
Sep 7, 2023
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 30, 2024
Results first posted
Jan 13, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05741372
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
Sep 7, 2023
Primary completion
Dec 18, 2024
Completion
Dec 30, 2024
Results posted
Jan 13, 2026
Last update
Jan 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Digoxin · Furosemide

Start the discussion